Keyphrases
High-throughput
100%
Neutralizing Antibodies
100%
Clinical Assay
100%
SARS-CoV-2 Neutralizing Antibody
100%
COVID-19
85%
Virus
28%
Antibody Titer
28%
Titer
28%
SARS-CoV-2 Infection
28%
Immune Response
14%
Vaccination
14%
Protective Immune Response
14%
Monoclonal Antibody
14%
Clinical Samples
14%
Blood Samples
14%
Clinical Application
14%
Angiotensin-converting Enzyme 2 (ACE2)
14%
Causative Agents
14%
Natural Infection
14%
Human Serum
14%
Vesicular Stomatitis Virus
14%
Vaccine-induced Immunity
14%
Clinical Sensitivity
14%
Clinical Specificities
14%
Limit of Detection
14%
Plaque Reduction Neutralization Test
14%
PRNT50
14%
Luciferase
14%
Human Plasma
14%
Dosing Schedule
14%
Surrogate Virus
14%
Vero
14%
High-throughput Assay
14%
Dynamic Range
14%
Virus Assay
14%
Range Limits
14%
Parallelization
14%
SARS-CoV-2 Spike
14%
COVID-19 Vaccine
14%
Assay Performance
14%
Limit of Blank
14%
Equivalent Matrix
14%
SARS-CoV-2 Spike Glycoprotein
14%
Immunology and Microbiology
Antibody Titer
100%
Neutralizing Antibody
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Infection
63%
Virus
27%
Immune Response
18%
Titer
18%
Vesiculovirus
18%
Spike
18%
COVID-19
18%
Blood Plasma
9%
Antibody Response
9%
Monoclonal Antibody
9%
Glycoprotein
9%
Serum (Blood)
9%
Plaque Reduction Neutralization Test
9%
Pharmacology, Toxicology and Pharmaceutical Science
Neutralizing Antibody
100%
SARS Coronavirus
100%
Infection
63%
Vesiculovirus
18%
Glycoprotein
9%
Monoclonal Antibody
9%
Luciferase
9%
COVID-19 Vaccine
9%
Diseases
9%